Fortin, Elena
Lundin, Magnus
Mellbin, Linda
Norhammar, Anna
Näsman, Per
Smetana, Stina
Sörensson, Peder
Ferrannini, Ele
Rydén, Lars
Ferrannini, Giulia
Funding for this research was provided by:
Karolinska Institute
Article History
Received: 19 June 2023
Accepted: 2 August 2023
First Online: 11 August 2023
Declarations
:
: All patients signed consent to study participation following written and oral information. The study was conducted in compliance with principles in the Declaration of Helsinki, 1996 version, as well as in accordance with the ICH Harmonized Tripartite Guideline for Good Clinical Practice and applicable regulatory requirements. The protocol was approved by the Regional Ethics committee in Stockholm (Dnr 2015:4/11) and the trial is registered in the European Union Drug Regulating Authorities Clinical Trials Database (EudraCT) with the number 2015-004571-73. The funder had no role in design and conduct of the trial.
: Not applicable.
: ML: has no conflicts of interest related to this work.LM: has no conflicts of interest related to this work.AN: has received research grants from the Swedish Heart-Lung Foundation and honoraria for lectures and consulting from Astra Zeneca, Boehringer-Ingelheim, Novo Nordisk.PN: has no conflicts of interest related to this work.SS: has no conflicts of interest related to this work.PS: has no conflicts of interest related to this work.E. Ferrannini: has no conflicts of interest related to this work.LR: has received research grants from the Swedish Heart-Lung Foundation, Erling Perssons Foundation, Region Stockholm (ALF), Boehringer-Ingelheim and honoraria for lectures and consulting from Bayer, Boehringer-Ingelheim, Novo Nordisk.GF: has no conflicts of interest related to this work.